As part of the DZP Future project addressed to the venture capital and startup market, DZP advised intoDNA on the A Series financing round. The advice to the company and some of the investors included negotiating and preparing an investment agreement and corporate governance rules, and developing the principles of the company’s transformation and the assumptions of the incentive scheme.
IntoDNA is a biotechnological start-up from Cracow, which has developed a breakthrough DNA testing technology - SensiTive Recognition of Individual DNA Ends (STRIDE).
IntoDNA is one of the most dynamically developing startups in the biotechnology industry, arousing the interest of leading venture capital funds and so-called big pharma, with its groundbreaking, patented technology for testing DNA damage.
Multidisciplinary legal support was coordinated by Maciej Zajda, in cooperation with dr Maciej Goszczyk and Jakub Kubalski.